MoonLake Immunotherapeutics
NASDAQ:MLTX
50.67 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | MoonLake Immunotherapeutics |
Symbool | MLTX |
Munteenheid | USD |
Prijs | 50.67 |
Beurswaarde | 3,186,565,362 |
Dividendpercentage | 0% |
52-weken bereik | 35.53 - 64.98 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jorge Santos da Silva |
Website | https://www.moonlaketx.com |
An error occurred while fetching data.
Over MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)